

16 JUNE 2025

CHAIR TO SEEK RE-ELECTION; DIRECTOR NOMINATIONS

DUNEDIN, New Zealand – Pacific Edge (NZX, ASX: PEB) today advises Chairman Chris Gallaher has accepted an invitation by the company’s Directors to seek re-election to the Board at the company’s Annual Shareholders’ Meeting (ASM) to be held on Wednesday 6 August 2025 starting at 1.00pm in Auckland.

Pacific Edge’s Directors extended the invitation because they believe shareholders’ best interests are served with the continuity and stability of Mr Gallaher’s leadership while the company continues to navigate the loss of Medicare coverage for Cxbladder products.

In September 2024 Mr Gallaher signaled his intention to step down this year (2025). He is also due to retire from the Board by rotation at the ASM in accordance with NZX Listing Rule 2.7.1. but will now be standing for re-election. Independent Directors Sarah Park and Tony Barclay, who are also due to retire by rotation in accordance with NZX Listing Rule 2.7.1, have indicated they will also stand for re-election.

Mr Gallaher said: “The inclusion of Cxbladder Triage in the American Urological Association’s new microhematuria guideline has allowed Pacific Edge to view the Local Coverage Determination¹ that ended Medicare coverage of our tests through a different lens. As we move through the process to seek re-coverage, I am happy to continue as Chairman to ensure we have Board stability and continuity.”

DIRECTOR NOMINATIONS

For the purposes of Listing Rule 2.3.2, Pacific Edge meanwhile advises that the closing date for Director nominations is Tuesday 1 July 2025.

All nominations must be received by 4.00pm on the closing date. Nominations may only be made by a shareholder entitled to attend and vote at the Annual Shareholder Meeting and must be accompanied by a consent in writing by the nominated person.

Nominations should be either emailed to investors@pacificedge.co.nz or addressed to:

Director Nominations
Pacific Edge Limited
PO Box 56
Dunedin 9016
New Zealand

Further details, including proxy voting forms and details of resolutions, will be provided in the Notice of Meeting, which will be sent to shareholders prior to the meeting.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

¹The Genetic Tests for Oncology (Specific Tests) (L39365) Local Coverage Determination was finalized by Novitas, the Medicare Administrative Contractor with responsibility for Pacific Edge’s laboratory, in January 2025 and it became effective in April 2025.

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.